Company

Zymedi

Pharmaceutical Manufacturing Kr 11 employees

Employees: 11
Contacts: 1
Emails: 1

zymedi.com LinkedIn Crunchbase

Zymedi Overview

Headquarters: Kr
Website: zymedi.com
Industry: Pharmaceutical Manufacturing
Employees: 11
Founded: 2019
Funding: 12.1M
NAICS: Pharmaceutical and Medicine Manufacturing

Medicinal and Botanical Manufacturing

Pharmaceutical Preparation Manufacturing

Keywords

ARS KARS1 ZM-A001 ZM-C001 ZM-C101

About Zymedi

Zymedi is a clinical-stage biopharmaceutical company focused on transforming the role of ARSs (Aminoacyl-tRNA Synthetases) as a novel target for discovering and developing treatments for serious, life-threatening conditions lacking effective therapies or standard care. Our lead asset, ZMA001, is a first-in-class therapeutic that targets Lysyl-tRNA synthetase 1 (KARS1). By controlling monocyte and macrophage infiltration to inhibit inflammation in pulmonary blood vessels, ZMA001 is being developed as a treatment for pulmonary arterial hypertension (PAH). Currently in Phase I trials through a CRADA with the U.S. NIH, ZMA001 shows promise in addressing the root causes of PAH, a market projected to reach $9.7 billion by 2028.

Zymedi Contact Details

People in AeroLeads: 4
With contact data: 1
Email contacts: 1; 25.0% coverage

Zymedi Org Chart

Sample employees and titles

Name	Title	Location	Contact
Minjo Kim	General Counsel - Director of Strategy and Planning at Zymedi	Seoul, South Korea, Korea, Republic of	View
Nam Hoon Kwon	Cto/evp, Zymedi, Co. Ltd.	Incheon, South Korea, Korea, Republic of	View
Oliver Kim	CFO at Zymedi	Incheon, South Korea, United States	Email
Sunghoon Kim	Founder & CEO, Zymedi	Seoul, South Korea, Korea, Republic of	View